Protagonist Therapeutics Current Ratio 2015-2022 | PTGX
Protagonist Therapeutics current ratio from 2015 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Protagonist Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-12-31 |
$0.24B |
$0.03B |
7.80 |
| 2022-09-30 |
$0.28B |
$0.04B |
7.53 |
| 2022-06-30 |
$0.30B |
$0.04B |
7.59 |
| 2022-03-31 |
$0.34B |
$0.04B |
7.86 |
| 2021-12-31 |
$0.34B |
$0.04B |
7.74 |
| 2021-09-30 |
$0.33B |
$0.04B |
8.37 |
| 2021-06-30 |
$0.37B |
$0.04B |
8.65 |
| 2021-03-31 |
$0.29B |
$0.04B |
8.27 |
| 2020-12-31 |
$0.32B |
$0.04B |
7.84 |
| 2020-09-30 |
$0.20B |
$0.04B |
5.29 |
| 2020-06-30 |
$0.22B |
$0.04B |
6.15 |
| 2020-03-31 |
$0.13B |
$0.04B |
3.46 |
| 2019-12-31 |
$0.15B |
$0.04B |
4.10 |
| 2019-09-30 |
$0.14B |
$0.03B |
4.68 |
| 2019-06-30 |
$0.14B |
$0.03B |
4.12 |
| 2019-03-31 |
$0.12B |
$0.02B |
5.02 |
| 2018-12-31 |
$0.14B |
$0.03B |
5.26 |
| 2018-09-30 |
$0.15B |
$0.02B |
6.12 |
| 2018-06-30 |
$0.14B |
$0.03B |
4.69 |
| 2018-03-31 |
$0.14B |
$0.03B |
4.19 |
| 2017-12-31 |
$0.15B |
$0.04B |
3.55 |
| 2017-09-30 |
$0.10B |
$0.05B |
1.87 |
| 2017-06-30 |
$0.07B |
$0.01B |
7.38 |
| 2017-03-31 |
$0.07B |
$0.01B |
8.68 |
| 2016-12-31 |
$0.08B |
$0.01B |
12.94 |
| 2016-09-30 |
$0.10B |
$0.01B |
19.12 |
| 2016-06-30 |
$0.02B |
$0.00B |
5.45 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.01B |
$0.00B |
7.34 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.078B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
